Evidence map›Paper›PMID 37306233›Full record

ArticleEMBO reports2023

SRSF3 shapes the structure of miR-17-92 cluster RNA and promotes selective processing of miR-17 and miR-20a.

Madara Ratnadiwakara, Mohamed Nm Bahrudeen, Erika Aikio, Piia Takabe, Rebekah M Engel, Zileena Zahir, Thierry Jardé, Paul J McMurrick, Helen E Abud, Minna-Liisa Änkö

Open access · hybridAbstract read
In one paragraph

Article in EMBO reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Exploring the multifunctionality of SR proteins.Biochemical Society transactions · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Madara RatnadiwakaraHudson Institute of Medical Research, Clayton, Vic., Australia.ORCID 0000-0001-7252-1823
Mohamed Nm BahrudeenFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID 0000-0003-3717-0583
Erika AikioFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID 0009-0005-5316-7124
Piia TakabeFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Rebekah M EngelDepartment of Anatomy and Developmental Biology, Monash University, Clayton, Vic., Australia.
Zileena ZahirHudson Institute of Medical Research, Clayton, Vic., Australia.
Thierry JardéHudson Institute of Medical Research, Clayton, Vic., Australia.ORCID 0000-0001-7483-8672
Paul J McMurrickDepartment of Surgery, Cabrini Health, Cabrini Monash University, Malvern, Vic., Australia.
Helen E AbudDepartment of Anatomy and Developmental Biology, Monash University, Clayton, Vic., Australia.
Minna-Liisa ÄnköHudson Institute of Medical Research, Clayton, Vic., Australia.ORCID 0000-0003-0446-3566
Tampere University · FIDiscovery Institute · USHudson Institute of Medical Research · AUCabrini Hospital · AU

Funding

DHAC | National Health and Medical Research Council (NHMRC) GNT1010429DHAC | National Health and Medical Research Council (NHMRC) GNT1043092DHAC | National Health and Medical Research Council (NHMRC) GNT1100531DHAC | National Health and Medical Research Council (NHMRC) GNT1138870Let's Beat Bowel Cancer (LBBC)Ron Evans FoundationSigrid Juséliuksen Säätiö (Sigrid Jusélius Stiftelse)Victorian Government Oparational Infrastructure Support Scheme
6 · The paper itself

Abstract

MicroRNA (miRNA) biogenesis is tightly regulated to maintain distinct miRNA expression patterns. Almost half of mammalian miRNAs are generated from miRNA clusters, but this process is not well understood. We show here that Serine-arginine rich splicing factor 3 (SRSF3) controls the processing of miR-17-92 cluster miRNAs in pluripotent and cancer cells. SRSF3 binding to multiple CNNC motifs downstream of Drosha cleavage sites within miR-17-92 is required for the efficient processing of the cluster. SRSF3 depletion specifically compromises the processing of two paralog miRNAs, miR-17 and miR-20a. In addition to SRSF3 binding to the CNNC sites, the SRSF3 RS-domain is essential for miR-17-92 processing. SHAPE-MaP probing demonstrates that SRSF3 binding disrupts local and distant base pairing, resulting in global changes in miR-17-92 RNA structure. Our data suggest a model where SRSF3 binding, and potentially its RS-domain interactions, may facilitate an RNA structure that promotes miR-17-92 processing. SRSF3-mediated increase in miR-17/20a levels inhibits the cell cycle inhibitor p21, promoting self-renewal in normal and cancer cells. The SRSF3-miR-17-92-p21 pathway operates in colorectal cancer, linking SRSF3-mediated pri-miRNA processing and cancer pathogenesis.

Indexed as

MicroRNAsAnimalsMammalsRNA Processing, Post-TranscriptionalMicroRNAscolorectal cancermiR-17-92pri-miRNA processingserine-arginine rich splicing factor 3SHAPE-MaP

Identifiers

PMID37306233
PMCPMC10328067
OpenAlexW4380290721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.